Day One Biopharmaceuticals, Inc. NASDAQ:DAWN

Founder-led company

Day One Biopharmaceuticals stock price today

$6.81
-6.06
-47.09%
Financial Health
0
1
2
3
4
5
6
7
8
9

Day One Biopharmaceuticals stock price monthly change

-15.38%
month

Day One Biopharmaceuticals stock price quarterly change

-15.38%
quarter

Day One Biopharmaceuticals stock price yearly change

-14.88%
year

Day One Biopharmaceuticals key metrics

Market Cap
1.27B
Enterprise value
750.25M
P/E
-5.99
EV/Sales
N/A
EV/EBITDA
-5.48
Price/Sales
N/A
Price/Book
2.51
PEG ratio
-0.11
EPS
-2.48
Revenue
N/A
EBITDA
-235.09M
Income
-208.93M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Day One Biopharmaceuticals stock price history

Day One Biopharmaceuticals stock forecast

Day One Biopharmaceuticals financial statements

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Profit margin
Jun 2023 0 -45.86M
Sep 2023 0 -46.15M
Dec 2023 560K -54.51M -9734.11%
Mar 2024 0 -62.41M
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Analyst Estimates
Mar 2024 0 -62.41M
Sep 2025 32.85M -33.38M -101.6%
Oct 2025 32.85M -42.40M -129.06%
Dec 2025 40.06M -39.22M -97.91%
  • Analysts Price target

  • Financials & Ratios estimates

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Earnings per share (EPS)
2023-11-06 -0.6 -0.54
2024-02-26 -0.57 -0.64
2024-05-06 -0.67 -0.72
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Debt to assets
Jun 2023 450756000 24.70M 5.48%
Sep 2023 414179000 818.25M 197.56%
Dec 2023 376048000 29.50M 7.85%
Mar 2024 326645000 29.83M 9.13%
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Cash Flow
Jun 2023 -42.43M 20.27M 162.10M
Sep 2023 -37.06M 88.91M 115K
Dec 2023 -41.37M 30.38M 597K
Mar 2024 -49.72M 89.28M 48K

Day One Biopharmaceuticals alternative data

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Employee count
Sep 2023 124
Oct 2023 124
Nov 2023 124
Dec 2023 133
Jan 2024 133
Feb 2024 133
Mar 2024 155
Apr 2024 155
May 2024 155
Jun 2024 174
Jul 2024 174

Day One Biopharmaceuticals other data

37.43% -47.39%
of DAWN is owned by hedge funds
24.50M -35.72M
shares is hold by hedge funds

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 35781
Mar 2024 0 40000
Apr 2024 0 10000
May 2024 0 113357
Jun 2024 0 40000
Jul 2024 0 20000
Aug 2024 827586 18748
Sep 2024 0 30000
Oct 2024 0 500
Nov 2024 0 58027
Dec 2024 0 30000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
BLACKMAN SAMUEL C. officer: HEAD OF .. Common Stock 30,000 $13.31 $399,330
Sale
BENDER JEREMY director, officer: CHIEF EXECUT..
Common Stock 10,554 $13.21 $139,418
Sale
BLACKMAN SAMUEL C. officer: HEAD OF .. Common Stock 2,206 $13.21 $29,141
Sale
DUBOW ADAM officer: GENERAL COUNSEL
Common Stock 3,165 $13.21 $41,810
Sale
YORK CHARLES N II officer: COO, CFO AND SECRETARY
Common Stock 2,602 $13.21 $34,372
Option
BENDER JEREMY director, officer: CHIEF EXECUT..
Restricted Stock Unit (RSU) 11,687 N/A N/A
Option
BENDER JEREMY director, officer: CHIEF EXECUT..
Common Stock 11,687 N/A N/A
Option
BENDER JEREMY director, officer: CHIEF EXECUT..
Common Stock 4,750 N/A N/A
Option
BENDER JEREMY director, officer: CHIEF EXECUT..
Common Stock 3,562 N/A N/A
Option
BENDER JEREMY director, officer: CHIEF EXECUT..
Restricted Stock Unit (RSU) 4,750 N/A N/A
Insider Compensation
Dr. Jeremy Bender M.B.A., Ph.D. (1972) Chief Executive Officer, Pres & Director
$481,360
Dr. Samuel C. Blackman M.D., Ph.D. (1969) Co-Founder & Chief Medical Officer $477,100
Ms. Julie Papanek Grant M.B.A. (1982) Co-Founder & Chair of the Board
$62,910
Thursday, 26 December 2024
zacks.com
Wednesday, 25 December 2024
seekingalpha.com
Tuesday, 17 December 2024
globenewswire.com
Wednesday, 20 November 2024
globenewswire.com
Monday, 18 November 2024
globenewswire.com
Wednesday, 6 November 2024
zacks.com
Wednesday, 30 October 2024
seekingalpha.com
zacks.com
globenewswire.com
prnewswire.com
Monday, 21 October 2024
zacks.com
Wednesday, 16 October 2024
globenewswire.com
Wednesday, 14 August 2024
investorplace.com
Tuesday, 30 July 2024
zacks.com
globenewswire.com
globenewswire.com
Thursday, 25 July 2024
globenewswire.com
Wednesday, 19 June 2024
zacks.com
Tuesday, 18 June 2024
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Monday, 6 May 2024
globenewswire.com
Tuesday, 23 April 2024
globenewswire.com
Monday, 26 February 2024
globenewswire.com
Thursday, 1 February 2024
seekingalpha.com
Tuesday, 19 December 2023
GlobeNewsWire
Sunday, 23 July 2023
Seeking Alpha
Monday, 5 June 2023
The Motley Fool
Market Watch
Monday, 1 May 2023
Proactive Investors
Friday, 7 April 2023
Seeking Alpha
  • What's the price of Day One Biopharmaceuticals stock today?

    One share of Day One Biopharmaceuticals stock can currently be purchased for approximately $6.81.

  • When is Day One Biopharmaceuticals's next earnings date?

    Unfortunately, Day One Biopharmaceuticals's (DAWN) next earnings date is currently unknown.

  • Does Day One Biopharmaceuticals pay dividends?

    No, Day One Biopharmaceuticals does not pay dividends.

  • How much money does Day One Biopharmaceuticals make?

    Day One Biopharmaceuticals has a market capitalization of 1.27B. Day One Biopharmaceuticals made a loss 188.92M US dollars in net income (profit) last year or -$0.72 on an earnings per share basis.

  • What is Day One Biopharmaceuticals's stock symbol?

    Day One Biopharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "DAWN".

  • What is Day One Biopharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Day One Biopharmaceuticals?

    Shares of Day One Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Day One Biopharmaceuticals's key executives?

    Day One Biopharmaceuticals's management team includes the following people:

    • Dr. Jeremy Bender M.B.A., Ph.D. Chief Executive Officer, Pres & Director(age: 53, pay: $481,360)
    • Dr. Samuel C. Blackman M.D., Ph.D. Co-Founder & Chief Medical Officer(age: 56, pay: $477,100)
    • Ms. Julie Papanek Grant M.B.A. Co-Founder & Chair of the Board(age: 43, pay: $62,910)
  • Is Day One Biopharmaceuticals founder-led company?

    Yes, Day One Biopharmaceuticals is a company led by its founders Dr. Samuel C. Blackman M.D., Ph.D. and Ms. Julie Papanek Grant M.B.A..

  • How many employees does Day One Biopharmaceuticals have?

    As Jul 2024, Day One Biopharmaceuticals employs 174 workers, which is 12% more then previous quarter.

  • When Day One Biopharmaceuticals went public?

    Day One Biopharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 27 May 2021.

  • What is Day One Biopharmaceuticals's official website?

    The official website for Day One Biopharmaceuticals is dayonebio.com.

  • Where are Day One Biopharmaceuticals's headquarters?

    Day One Biopharmaceuticals is headquartered at 395 Oyster Point Boulevard, South San Francisco, CA.

  • How can i contact Day One Biopharmaceuticals?

    Day One Biopharmaceuticals's mailing address is 395 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 04840899.

Day One Biopharmaceuticals company profile:

Day One Biopharmaceuticals, Inc.

dayonebio.com
Exchange:

NASDAQ

Full time employees:

174

Industry:

Biotechnology

Sector:

Healthcare

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

395 Oyster Point Boulevard
South San Francisco, CA 94080

CIK: 0001845337
ISIN: US23954D1090
CUSIP: 23954D109